Summarized by Masters of Longevity from Longevity Technology.
Biolexis reported first-in-human Phase 1a data for BLX-7006 and will present the results.

Key Takeaways
- Phase 1a tested BLX-7006 in healthy human volunteers.
- Company will present data at ObesityWeek 2026 conference.
- These early results are exploratory and not efficacy proof.



